CARA Cara Therapeutics Inc: יחס שווי שוק לשווי בספרים

Cara Therapeutics, Inc. (CARA) operates on a virtual drug development model, utilizing external CMO facilities for synthesis. This GURU.Markets terminal chart provides data on the market capitalization to net assets ratio, with the metric currently at 0.97. Growth is driven by the loyalty of nephrology centers, while human capital is sustained through an option system for research chemists.

The P/BV ratio compares the issuer's market value to its net assets, determining the premium or discount to equity. By analyzing the historical P/BV level, an investor assesses asset quality and the risk of impairment. For Cara Therapeutics, Inc. (CARA), the decline in this metric reflects a loss of commercial potential due to failures in clinical trials. Eroding confidence in the platform is destroying the company's economic moat, signaling a high probability of prolonged stagnation.